31 March 2025 in PLOS ONE
Background: Acetaminophen (APAP) can be used for pain relief and fever alleviation, the overdose of which, however, may lead to the accumulation of N-acetyl-p-benzoquinone imine (NAPQI), inducing oxidative stress and liver damage. The natural compound SMND-309 has been shown to have hepatoprotective effects and potential antioxidant activity. However, its ability to alleviate acetaminophen-induced acute liver injury (AILI) has not been elucidated. Objective: To explore the protective effect of the natural compound SMND-309 against AILI and the potential mechanism. Methods: The AILI model was established using a mouse model and HepG2 cells for pathological evaluation and biochemical assays of mouse liver tissues to assess the level of liver injury. The effects of SMND-309 on cellular ROS levels and mitochondrial membrane potential were detected using DCFH-DA and JC-1 probes. Western blotting was performed to detect the expressions of Nrf2 signaling pathway and key proteins related to APAP metabolism in the combination of immunohistochemistry of liver tissues, with immunofluorescence assay used to detect whether Nrf2 undergoes nuclear translocation. Molecular docking, molecular dynamics simulation (MD) and biofilm layer interference (BLI) experiments were performed to detect the interaction of SMND-309 with Keap1. Results: SMND-309 improved histopathological changes in the liver, decreased alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH) levels, as well as attenuated oxidative stress injury and mitochondrial dysfunction in the HepG2 cell line. Further studies revealed that SMND-309 promoted nuclear translocation of Nrf2 and upregulated the expressions of glutamate-cysteine ligase catalytic subunit (GCLC), heme oxygenase 1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1). In addition, molecular docking and MD suggested that SMND-309 could bind Keap1 and identified possible binding modes, with BLI experiments confirming that SMND-309 directly interacted with Keap1. Conclusion: SMND-309 exerts hepatoprotective effects against AILI in an Nrf2-ARE signaling pathway-dependent manner.
13 October 2025 in Developmental & Comparative Immunology
24 April 2026 in Thoracic Cancer
Background: Ferroptosis is a novel research avenue for cancer therapy. The roles of Danshensu derivatives remain unclear. This study investigated the effect of Danshensu Ethyl Ester (DEE) on ferroptosis in non‐small cell lung cancer (NSCLC) cells. Methods: NSCLC cells were treated with DEE to assess ferroptosis markers, including reactive oxygen species (ROS), malondialdehyde (MDA), glutathione (GSH), and mitochondrial membrane potential (MMP), along with related protein expression. Molecular docking and dynamics simulations predicted the DEE‐SLC7A11 interaction. Intracellular cysteine levels were quantified by ELISA. The functional involvement of SLC7A11 was further verified through its knockdown and overexpression. The in vivo antitumor activity of DEE was assessed using a nude mouse xenograft model. Results: DEE treatment dose‐dependently promoted cell death in A549 and H1299 cells, accompanied by increased levels of ROS and MDA, reduced GSH and MMP, and downregulated expression of SLC7A11 and GPX4. These effects were reversed by ferroptosis inhibitor Ferrostatin‐1 (Fer‐1), confirming ferroptosis involvement. Mechanistically, DEE directly inhibited the transport function of SLC7A11 in a p53‐independent manner and also decreased p53 protein levels in wild‐type A549 cells. Consistently, DEE reduced intracellular cysteine content. Genetic silencing of SLC7A11 enhanced DEE‐induced ferroptosis, whereas its overexpression attenuated the effect. In vivo, DEE significantly suppressed tumor growth in a xenograft model, exhibiting efficacy comparable to that of paclitaxel. Conclusions: DEE inhibits NSCLC progression by inducing ferroptosis through the targeted inhibition of SLC7A11 transport function via a p53‐independent pathway, highlighting its potential as a novel therapeutic agent for NSCLC.